According to the recent research report titled ‘Asia Pacific Growth Hormone Market Forecast 2027 By Product, By Application, By Distribution Channel, Research Report, Country Outlook, COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share’ available with MarketStudyReport, Asia Pacific growth hormone market is poised to amass gains over USD 1.1 billion by 2027.

Rising awareness to treat growth hormone therapies, growing demand for amenities and technologies that facilitate early diagnosis, and the government launching several favorable initiatives that promote early diagnosis and affordable treatment facilities are some of the major factors driving the Asia Pacific growth hormone market growth.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4384860/  

In Asia Pacific, the healthcare sector is rapidly expanding as governments increase their spending in developing world-class medical facilities for inhabitants. This coupled with growing number of pharmacies are aiding towards the market expansion.

The Asia Pacific growth hormone marketplace is segmented into product type, application landscape, distribution channel, and regional landscape.

Based on product landscape, the report cites that the powder segment accounted for USD 419 million in 2020 and is expected to grow significantly through the forecast duration.

The application segment of this business space is segregated into idiopathic short stature, growth hormone deficiency, small for gestational age, turner syndrome, and others. Asia-Pacific growth hormone market from Turner syndrome application is estimated to reach 8.7% CAGR through 2027 given the increased prevalence of the disease and focus toward adopting early diagnosis solutions.

Moving forward the distribution channel, the market is classified into hospital pharmacy, retail pharmacy, and online med stores. Among these, hospital pharmacies accounted for USD 381.5 million in 2020 and is poised to have steady growth through the study timeline. As these pharmacies are placed within the hospital, patients have better access to rare, expensive, and life-saving medications during an emergency, further contributing towards the overall industry remuneration.

The geographical landscape of Asia Pacific growth hormone industry spans across India, China, Japan, Indonesia, South Korea, Australia, Thailand, The Philippines, and Singapore. Japan market was valued USD 164 million in 2020 and is predicted to have exponential growth through the analysis timeframe, primarily driven by government focus towards mitigating growing growth hormone cases and rising cognizance regarding the disease management.

The leading companies of Asia Pacific growth hormone business sphere are Pfizer Inc., Ferring B V, Novo Nordisk A/S, Merck KGaA, Anhui Anke Biotechnology (Group) Co., Ipsen S A Ltd., Eli Lily and Company, Genetech Inc. (Roche Group), LG Chem Ltd., and Novartis AG.